FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Chamberlin

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Anatomy

Occupations

Drug Design

Procedures

Combinatorial Chemistry Techniques

Co-author Network

Publications

TOP 3
Jiewen Zhu; Guideng Li; Xiaoqin Lin; Xiao-Long Qiu; Guikai Wu; Longen Zhou; Ravi Bhatia; A Richard Chamberlin; Chi-Fen Chen; Phang-Lang Chen; Erin Goldblatt; Chun-Mei Hu; Heiko Konig; Wen-Hwa Lee
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Mihaela Mihailescu; Rishi G Vaswani; Eduardo Jardón-Valadez; Francisco Castro-Román; J Alfredo Freites; David L Worcester; A Richard Chamberlin; Douglas J Tobias; Stephen H White
Acyl-chain methyl distributions of liquid-ordered and -disordered membranes.
Xiao-Long Qiu; Guideng Li; Guikai Wu; Jiewen Zhu; Longen Zhou; Phang-Lang Chen; A Richard Chamberlin; Wen-Hwa Lee
Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Chamberlin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jiewen Zhu; Guideng Li; Xiaoqin Lin; Xiao-Long Qiu; Guikai Wu; Longen Zhou; Ravi Bhatia; A Richard Chamberlin; Chi-Fen Chen; Phang-Lang Chen; Erin Goldblatt; Chun-Mei Hu; Heiko Konig; Wen-Hwa Lee
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
EMBO molecular medicine 2013;5(3):353-65.
2011: Mihaela Mihailescu; Rishi G Vaswani; Eduardo Jardón-Valadez; Francisco Castro-Román; J Alfredo Freites; David L Worcester; A Richard Chamberlin; Douglas J Tobias; Stephen H White
Acyl-chain methyl distributions of liquid-ordered and -disordered membranes.
Biophysical journal 2011;100(6):1455-62.
2009: Xiao-Long Qiu; Guideng Li; Guikai Wu; Jiewen Zhu; Longen Zhou; Phang-Lang Chen; A Richard Chamberlin; Wen-Hwa Lee
Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues.
Journal of medicinal chemistry 2009;52(6):1757-67.
2009: Xiao-Long Qiu; Jiewen Zhu; Guikai Wu; Wen-Hwa Lee; A Richard Chamberlin
Stereoselective synthesis of chiral IBR2 analogues.
The Journal of organic chemistry 2009;74(5):2018-27.
2009: Rishi G Vaswani; Agenor Limon; Jorge Mauricio Reyes-Ruiz; Ricardo Miledi; A Richard Chamberlin
Design, synthesis, and biological evaluation of a scaffold for iGluR ligands based on the structure of (-)-kaitocephalin.
Bioorganic & medicinal chemistry letters 2009;19(1):132-5.
2008: Naoe Okamura; Stephen A Habay; Joanne Zeng; A Richard Chamberlin; Rainer K Reinscheid
Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.
The Journal of pharmacology and experimental therapeutics 2008;325(3):893-901.
2008: Erin Tappan; A Richard Chamberlin
Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site.
Chemistry & biology 2008;15(2):167-74.
2007: Jamie L Cohen; A Richard Chamberlin
Diastereoselective synthesis of glutamate-appended oxolane rings: synthesis of (s)-(+)-lycoperdic acid.
The Journal of organic chemistry 2007;72(24):9240-7.
2006: Trevor T Charvat; Deborah J Lee; W Edward Robinson; A Richard Chamberlin
Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase.
Bioorganic & medicinal chemistry 2006;14(13):4552-67.
2006: David A Colby; A Richard Chamberlin
Pharmacophore identification: the case of the ser/thr protein phosphatase inhibitors.
Mini reviews in medicinal chemistry 2006;6(6):657-65.
2006: Jamie L Cohen; Agenor Limon; Ricardo Miledi; A Richard Chamberlin
Design, synthesis, and biological evaluation of a scaffold for iGluR ligands based on the structure of (-)-dysiherbaine.
Bioorganic & medicinal chemistry letters 2006;16(8):2189-94.
2006: matthew alexander; Michael D Burkart; Michael S Leonard; Padma Portonovo; Bo Liang; Xiaobin Ding; Madeleine M Joullié; Brian M Gulledge; James B Aggen; A Richard Chamberlin; Joel S Sandler; William Fenical; Jian Cui; Santosh J Gharpure; Alexei Polosukhin; Hai-Ren Zhang; P Andrew Evans; Adam Richardson; Mary Kay Harper; Chris M Ireland; Binh G Vong; Thomas P Brady; Emmanuel A Theodorakis; James J La Clair
A central strategy for converting natural products into fluorescent probes.
Chembiochem : a European journal of chemical biology 2006;7(3):409-16.
2005: C Sean Esslinger; Shailesh Agarwal; John M Gerdes; Paul A Wilson; Erin S Davis; Alicia N Awes; Erin O'Brien; Teri Mavencamp; Hans P Koch; David Poulsen; Joseph F Rhoderick; A Richard Chamberlin; Michael P Kavanaugh; Richard J Bridges
The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3.
Neuropharmacology 2005;49(6):850-61.
2005: Xiaohong Shou; Ricardo Miledi; A Richard Chamberlin
Indole- and indoline-based kainate analogues with antagonist activity at ionotropic glutamate receptors.
Bioorganic & medicinal chemistry letters 2005;15(17):3942-7.
2005: Joel S Sandler; William Fenical; Brian M Gulledge; A Richard Chamberlin; James J La Clair
Fluorescent profiling of natural product producers.
Journal of the American Chemical Society 2005;127(26):9320-1.
2004: Matthew E Hart; A Richard Chamberlin; Cecilia C Walkom; Jennette A Sakoff; Adam McCluskey
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
Bioorganic & medicinal chemistry letters 2004;14(8):1969-73.
2003: Brian M Gulledge; James B Aggen; Hugo Eng; Khuloud Sweimeh; A Richard Chamberlin
Microcystin analogues comprised only of Adda and a single additional amino acid retain moderate activity as PP1/PP2A inhibitors.
Bioorganic & medicinal chemistry letters 2003;13(17):2907-11.
2003: Brian M Gulledge; James B Aggen; A Richard Chamberlin
Linearized and truncated microcystin analogues as inhibitors of protein phosphatases 1 and 2A.
Bioorganic & medicinal chemistry letters 2003;13(17):2903-6.
2003: David A Colby; Wen Liu; James E Sheppeck; Hsien-Bin Huang; Angus Nairn; A Richard Chamberlin
A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure.
Bioorganic & medicinal chemistry letters 2003;13(9):1601-5.
2003: Wen Liu; James E Sheppeck; David A Colby; Hsien-Bin Huang; Angus Nairn; A Richard Chamberlin
The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.
Bioorganic & medicinal chemistry letters 2003;13(9):1597-600.
2002: B M Gulledgea; J B Aggena; H-B Huangb; A C Nairnc; A Richard Chamberlin
The microcystins and nodularins: cyclic polypeptide inhibitors of PP1 and PP2A.
Current medicinal chemistry 2002;9(22):1991-2003.
2002: C Sean Esslinger; Jody Titus; Hans Koch; Richard Bridges; A Richard Chamberlin
Methylation of L-trans-2,4-pyrrolidine dicarboxylate converts the glutamate transport inhibitor from a substrate to a non-substrate inhibitor.
Bioorganic & medicinal chemistry 2002;10(11):3509-15.
2002: Peter O Krutzik; A Richard Chamberlin
Rapid solid-phase synthesis of DNA-binding pyrrole-imidazole polyamides.
Bioorganic & medicinal chemistry letters 2002;12(16):2129-32.
2002: Dean Phillips; A Richard Chamberlin
Total synthesis of dysiherbaine.
The Journal of organic chemistry 2002;67(10):3194-201.
2002: Amy Lew; Peter O Krutzik; Matthew E Hart; A Richard Chamberlin
Increasing rates of reaction: microwave-assisted organic synthesis for combinatorial chemistry.
Journal of combinatorial chemistry 2002;4(2):95-105.
2002: Amy Lew; A Richard Chamberlin
The preparation of phenyl-stilbene derivatives using the safety catch linker.
Methods in molecular biology (Clifton, N.J.) 2002;201():93-109.
2002: Peter O Krutzik; A Richard Chamberlin
Synthesis of DNA-binding polyamides. Robust solid-phase methods for coupling heterocyclic aromatic amino acids.
Methods in molecular biology (Clifton, N.J.) 2002;201():77-92.
2001: WJ Fischer; Ian Garthwaite; Christopher O Miles; Kathryn M Ross; James B Aggen; A Richard Chamberlin; Neale R Towers; Daniel Dietrich
Congener-independent immunoassay for microcystins and nodularins.
Environmental science & technology 2001;35(24):4849-56.
2001: Christopher M Anderson; Richard J Bridges; A Richard Chamberlin; K Shimamoto; Y Yasuda-Kamatani; Raymond Swanson
Differing effects of substrate and non-substrate transport inhibitors on glutamate uptake reversal.
Journal of neurochemistry 2001;79(6):1207-16.
1999: Amy Lew; A Richard Chamberlin
Blockers of human T cell Kv1.3 potassium channels using de novo ligand design and solid-phase parallel combinatorial chemistry.
Bioorganic & medicinal chemistry letters 1999;9(23):3267-72.
1999: Hans P Koch; Michael P Kavanaugh; C Sean Esslinger; N Zerangue; JM Humphrey; Susan Amara; A Richard Chamberlin; Richard J Bridges
Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters.
Molecular pharmacology 1999;56(6):1095-104.
1999: Hans P Koch; A Richard Chamberlin; Richard J Bridges
Nontransportable inhibitors attenuate reversal of glutamate uptake in synaptosomes following a metabolic insult.
Molecular pharmacology 1999;55(6):1044-8.
1999: Richard J Bridges; Michael P Kavanaugh; A Richard Chamberlin
A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system.
Current pharmaceutical design 1999;5(5):363-79.
1999: James B Aggen; JM Humphrey; CM Gauss; Hsien-Bin Huang; Angus Nairn; A Richard Chamberlin
The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity.
Bioorganic & medicinal chemistry 1999;7(3):543-64.
1998: C Sean Esslinger; Hans P Koch; Michael P Kavanaugh; D P Philips; A Richard Chamberlin; Charles M Thompson; Richard J Bridges
Structural determinants of substrates and inhibitors: probing glutamate transporters with 2,4-methanopyrrolidine-2,4-dicarboxylate.
Bioorganic & medicinal chemistry letters 1998;8(21):3101-6.
1998: A Richard Chamberlin; Hans P Koch; Richard J Bridges
Design and synthesis of conformationally constrained inhibitors of high-affinity, sodium-dependent glutamate transporters.
Methods in enzymology 1998;296():175-89.
1998: Lance Steward; A Richard Chamberlin
Protein engineering with nonstandard amino acids.
Methods in molecular biology (Clifton, N.J.) 1998;77():325-54.
1997: James E Sheppeck; CM Gauss; A Richard Chamberlin
Inhibition of the Ser-Thr phosphatases PP1 and PP2A by naturally occurring toxins.
Bioorganic & medicinal chemistry 1997;5(9):1739-50.
1997: C L Willis; D L Dauenhauer; JM Humphrey; A Richard Chamberlin; AL Buller; Daniel T Monaghan; Richard J Bridges
Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine-dicarboxylate: enhanced excitotoxic potency and selectivity.
Toxicology and applied pharmacology 1997;144(1):45-55.
1997: C L Willis; D A Wacker; Richard D Bartlett; David Bleakman; D Lodge; A Richard Chamberlin; Richard J Bridges
Irreversible inhibition of high-affinity [3H]kainate binding by a novel photoactivatable analogue: (2'S,3'S,4'R)-2'-carboxy-4'-(2-diazo-1-oxo-3, 3,3-trifluoropropyl)-3'-pyrrolidinyl acetate.
Journal of neurochemistry 1997;68(4):1503-10.
1996: C L Willis; J M Humphrey; Hans P Koch; J A Hart; T Blakely; L Ralston; C A Baker; S Shim; M Kadri; A Richard Chamberlin; Richard J Bridges
L-trans-2,3-pyrrolidine dicarboxylate: characterization of a novel excitotoxin.
Neuropharmacology 1996;35(5):531-9.
1994: S Miller; Richard J Bridges; A Richard Chamberlin; Carl W Cotman
Pharmacological dissociation of glutamatergic metabotropic signal transduction pathways in cortical astrocytes.
European journal of pharmacology 1994;269(2):235-41.
1994: Richard J Bridges; F E Lovering; H Koch; Carl W Cotman; A Richard Chamberlin
A conformationally constrained competitive inhibitor of the sodium-dependent glutamate transporter in forebrain synaptosomes: L-anti-endo-3,4-methanopyrrolidine dicarboxylate.
Neuroscience letters 1994;174(2):193-7.
1992: J D Bain; Christopher Switzer; A Richard Chamberlin; S A Benner
Ribosome-mediated incorporation of a non-standard amino acid into a peptide through expansion of the genetic code.
Nature 1992;356(6369):537-9.
1991: J D Bain; E S Diala; Charles G Glabe; D A Wacker; M H Lyttle; Thomas A Dix; A Richard Chamberlin
Site-specific incorporation of nonnatural residues during in vitro protein biosynthesis with semisynthetic aminoacyl-tRNAs.
Biochemistry 1991;30(22):5411-21.
1991: Richard J Bridges; M S Stanley; M W Anderson; Carl W Cotman; A Richard Chamberlin
Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diastereomer.
Journal of medicinal chemistry 1991;34(2):717-25.
1983: D T Monaghan; M C McMills; A Richard Chamberlin; Carl W Cotman
Synthesis of [3H]2-amino-4-phosphonobutyric acid and characterization of its binding to rat brain membranes: a selective ligand for the chloride/calcium-dependent class of L-glutamate binding sites.
Brain research 1983;278(1-2):137-44.